Results 231 to 240 of about 399,014 (392)

Structure-Activity Relationship Studies on Potential Non-Nucleoside DABO-Like Inhibitors of HIV-1 Reverse Transcriptase [PDF]

, 2000
Roberta Costi, Roberto Di Santo, Marino Artico, Silvio Massa, Antonio Lavecchia, Tiziana Marceddu, Laura Sanna, Paolo La Colla, Maria Elena Marongiu   +8 more
openalex   +1 more source

Nucleoside reverse transcriptase inhibitors possess intrinsic anti-inflammatory activity

Science, 2014
B. Fowler, Bradley D. Gelfand, Younghee Kim, N. Kerur, Valeria Tarallo, Yoshio Hirano, Shoba Amarnath, D. Fowler, M. Radwan, M. Young, K. Pittman, P. Kubes, H. Agarwal, K. Parang, D. Hinton, A. Bastos-Carvalho, Shengjian Li, T. Yasuma, Takeshi Mizutani, Reo Yasuma, Charles B. Wright, J. Ambati   +21 more
semanticscholar   +1 more source

Drug resistance mutations to integrase inhibitors, proteinase, and reverse transcriptase inhibitors in newly diagnosed HIV-1 infections in Hebei province, China, 2018-2022. [PDF]

Front Cell Infect Microbiol
Lu X, Li Y, Liu M, Wang Y, An N, Sun D, Li Q.   +6 more
europepmc   +1 more source

Resistance Profile of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibitor Abacavir (1592U89) after Monotherapy and Combination Therapy

, 2000
P. Richard Harrigan, Chris Stone, Phillip Griffin, Isabel Nájera, Stuart Bloor, Sharon D. Kemp, Margaret Tisdale, Brendan Larder   +7 more
openalex   +1 more source

High prevalence of reverse transcriptase inhibitors associated resistance mutations among people living with HIV on dolutegravir-based antiretroviral therapy in Francistown, Botswana. [PDF]

J Antimicrob Chemother
Choga OT, Lemogang GM, Choga WT, Muzanywa G, Shadreck TM, Ralegoreng C, Maruapula D, Moraka NO, Koofhethile CK, Mokgethi PT, Seru K, Zuze BJL, Montshosi P, Gobe I, Motswaledi MS, Musonda R, Mbulawa MB, Makhema J, Shapiro R, Lockman S, Chebani T, Nawa J, Bochena L, Moyo S, Gaseitsiwe S.   +24 more
europepmc   +1 more source

Correction for Underwood et al., "Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study". [PDF]

Antimicrob Agents Chemother, 2023
Underwood M, Horton J, Nangle K, Hopking J, Smith K, Aboud M, Wynne B, Sievers J, Stewart EL, Wang R.   +9 more
europepmc   +1 more source

Evidence for independent development of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid

, 2000
Philip Cunningham, Danielle G. Smith, Claudette Satchell, David A. Cooper, Bruce J. Brew   +4 more
openalex   +1 more source

What are the perceived advantages and disadvantages of non‐nucleoside reverse transcriptase inhibitors as first‐line therapy? [PDF]

, 2000
BG Gazzard
openalex   +1 more source

No accelerated progression of subclinical atherosclerosis with integrase strand transfer inhibitors compared to non-nucleoside reverse transcriptase inhibitors. [PDF]

J Antimicrob Chemother
García-Abellán J, García JA, Padilla S, Fernández-González M, Agulló V, Mascarell P, Botella Á, Gutiérrez F, Masiá M.   +8 more
europepmc   +1 more source

Associations between plasma nucleoside reverse transcriptase inhibitors concentrations and cognitive function in people with HIV. [PDF]

PLoS One, 2021
De Francesco D, Wang X, Dickinson L, Underwood J, Bagkeris E, Babalis DS, Mallon PWG, Post FA, Vera JH, Sachikonye M, Williams I, Khoo S, Sabin CA, Winston A, Boffito M, Pharmacokinetic and Clinical Observations in PeoPle Over fiftY (POPPY) study.   +15 more
europepmc   +1 more source